Curiac D

No ORCID on file · 1 paper in corpus

nonrandomized-trial 2025

First-in-Human Safety, Tolerability, Efficacy, and Pharmacokinetics of Pegfosimer Manganese (SN132D) for Contrast-Enhanced MRI of Breast Cancer

Investigative radiology ·doi:10.1097/rli.0000000000001164

OBJECTIVES: The primary objective of the first-in-human (FIH) study was to evaluate the safety and tolerability of the manganese (Mn)-based contrast agent pegfosimer manganese in participants with newly diagnosed breast cancer, and secondar…